LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) said Tagrisso has received marketing authorisation in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer. The company said the ap...
Original Article: AstraZeneca Announces Approval For Tagrisso In China